These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 33549553)

  • 1. Proteomics as a Path to More Refined Heart Failure Therapeutics.
    Januzzi JL; Murphy SP
    JACC Heart Fail; 2021 Apr; 9(4):278-280. PubMed ID: 33549553
    [No Abstract]   [Full Text] [Related]  

  • 2. Spironolactone improves the arrhythmogenic substrate in heart failure by preventing ventricular electrical activation delays associated with myocardial interstitial fibrosis and inflammation.
    Esposito CT; Varahan S; Jeyaraj D; Lu Y; Stambler BS
    J Cardiovasc Electrophysiol; 2013 Jul; 24(7):806-12. PubMed ID: 23489714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spironolactone used with mercaptomerin in the treatment of congestive cardiac failure.
    NORTH JD; HOWIE RN; SIMS FH
    Med J Aust; 1961 Jul; 48(2)():92-5. PubMed ID: 13729618
    [No Abstract]   [Full Text] [Related]  

  • 4. Spironolactone in patients with heart failure.
    Glick G
    N Engl J Med; 2000 Jan; 342(2):133; author reply 133-4. PubMed ID: 10636752
    [No Abstract]   [Full Text] [Related]  

  • 5. Mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction (HFpEF).
    Capuano A; Scavone C; Vitale C; Sportiello L; Rossi F; Rosano GM; Coats AJ
    Int J Cardiol; 2015 Dec; 200():15-9. PubMed ID: 26404747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of aldosterone and aldosterone-receptor antagonists in heart failure.
    Khan NU; Movahed A
    Rev Cardiovasc Med; 2004; 5(2):71-81. PubMed ID: 15184841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical use of spirolactone SC-9420 "Aldactone"].
    KUCHEL O; HORKY K; DONOCIK A
    Cas Lek Cesk; 1962 Jul; 101():962-7. PubMed ID: 14460149
    [No Abstract]   [Full Text] [Related]  

  • 8. PEARL-HF: prevention of hyperkalemia in patients with heart failure using a novel polymeric potassium binder, RLY5016.
    Buysse JM; Huang IZ; Pitt B
    Future Cardiol; 2012 Jan; 8(1):17-28. PubMed ID: 22185443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Apparently irreducible cardiac edema. Remarkable effect of a spirolactone].
    VIALA JJ; FATH A
    Lyon Med; 1961 May; 93():1217-20. PubMed ID: 13781098
    [No Abstract]   [Full Text] [Related]  

  • 10. [Aldostegone-antagonistic steroids as diuretics. Spironolactone in the treatment of hepatic and cardiac edemas].
    LEPPLA W; TIEFENSEE H
    Dtsch Med Wochenschr; 1961 Dec; 86():2395-402. PubMed ID: 14464199
    [No Abstract]   [Full Text] [Related]  

  • 11. Beta-blockers and spironolactone in heart failure.
    Kukin ML
    Curr Cardiol Rep; 2000 Mar; 2(2):87-9. PubMed ID: 10980877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist.
    Vardeny O; Claggett B; Anand I; Rossignol P; Desai AS; Zannad F; Pitt B; Solomon SD;
    Circ Heart Fail; 2014 Jul; 7(4):573-9. PubMed ID: 24812304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Aldactone (aldosterone antagonist SC-9, 420) in the treatment of the edemas of heart patients and cirrhotic patients. Bioclinical study].
    PAGET M; LANGERON L; CROCCEL L; ROUTIER G; CROCCEL E; PROTIN M
    J Sci Med Lille; 1962 May; 80():225-35. PubMed ID: 14483183
    [No Abstract]   [Full Text] [Related]  

  • 14. The SEISICAT study: a pilot study assessing efficacy and safety of spironolactone in cats with congestive heart failure secondary to cardiomyopathy.
    James R; Guillot E; Garelli-Paar C; Huxley J; Grassi V; Cobb M
    J Vet Cardiol; 2018 Feb; 20(1):1-12. PubMed ID: 29277469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spironolactone for Management of Heart Failure with Preserved Ejection Fraction: Whither to After TOPCAT?
    Mitter SS; Shah SJ
    Curr Atheroscler Rep; 2015 Nov; 17(11):64. PubMed ID: 26408016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibroblast Senescence as a Therapeutic Target of Myocardial Fibrosis: Beyond Spironolactone?
    Condorelli G; Jotti GS; Pagiatakis C
    J Am Coll Cardiol; 2016 May; 67(17):2029-31. PubMed ID: 27126530
    [No Abstract]   [Full Text] [Related]  

  • 17. [Spirolactones. Their use in the treatment of cardiac and cirrhotic edemas (apropos of 6 case reports)].
    JUSTIN-BESANCON L; LAROCHE C; NENNA A; ETIENNE JP; CREMER G
    Sem Hop; 1960 Dec; 36():3083-97. PubMed ID: 13791128
    [No Abstract]   [Full Text] [Related]  

  • 18. [Aldactone (antialdosterone SC-9420) in the treatment of the edema of cardiac and cirrhoticpatients. Bioclinical study. I].
    PAGET M; LANGERON L; CROCCEL L; ROUTIER G; CROCCEL E
    Ann Biol Clin (Paris); 1962; 20():497-524. PubMed ID: 14483184
    [No Abstract]   [Full Text] [Related]  

  • 19. Aldactone therapy in a peritoneal dialysis patient.
    Azar R; Hogede L; Carru V
    Nephrol Dial Transplant; 2003 Jun; 18(6):1232; author reply 1232-3. PubMed ID: 12748367
    [No Abstract]   [Full Text] [Related]  

  • 20. Spironolactone in the treatment of congestive heart failure.
    Lloyd SJ; Mauro VF
    Ann Pharmacother; 2000 Nov; 34(11):1336-40. PubMed ID: 11098350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.